Premium
Methotrexate with citrovorum factor rescue reduced chemotherapy toxicity in the management of gestational trophoblastic neoplasms
Author(s) -
Berkowitz Ross S.,
Goldstein Donald P.,
Jones Miles A.,
Marean Ann R.,
Bernstein Marilyn R.
Publication year - 1980
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19800201)45:3<423::aid-cncr2820450303>3.0.co;2-g
Subject(s) - medicine , methotrexate , rash , toxicity , gastroenterology , incidence (geometry) , chemotherapy , regimen , pharmacology , optics , physics
The comparative systemic toxicity of methotrexate (MTX) with citrovorum factor rescue (CF), MTX alone and actinomycin‐D (Act‐D) in the treatment of gestational trophoblastic neoplasms (GTN) was evaluated in the present study. Treatment with MTX‐CF was associated with only a 4% incidence (1 of 25 patients) of hepatic and/or hematologic toxicity and total absence of either a generalized rash or marked alopecia. In contrast, both MTX alone and Act‐D were associated with a 48% incidence (12 of 25 patients) of hepatic and/or hematologic toxicity. Actinomycin‐D also induced a generalized rash and marked alopecia in 24% (6 of 25 patients) and 52% (13 of 25 patients) of the patients respectively. We found that MTX‐CF is the least toxic single agent chemotherapeutic regimen in the management of GTN.